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background: Cystatin C is known as a novel filtration marker which is less affected by age, sex, muscle mass and a good predictor of adverse 
outcomes such as cardiovascular disease (CVD) or death. We investigated role of Cystatin C as a prognotic marker in patients with peripheral artery 
disease (PAD) undergoing percutaneous transluminal angioplasty (PTA).
methods: We evaluated 200 consecutive PAD patients treated with PTA from September, 2010 to September, 2012 at Severance Cardiovascular 
Hospital. Acute lower limb ischemia and intervention for graft were excluded. CIN was defined as increase ≥25% and/or ≥0.5 mg/dl in serum 
creatinine (Cr) at 48 h after PTA compared with baseline level. Adverse clinical events were defined as mortality, amputation, stroke, myocardial 
infarction, hemodialysis and target lesion revascularization. Multivariable logistic regression analysis was then performed to identify independent 
predictors of CIN and cox proportional hazards model was for adverse clinical events
results: Cystatin C >1.35 mg/dl was associated with significant increase in risk for CIN independent of serum Cr >1.5 mg/dl or estimated 
glomerular filtration rate (eGFR) <60 ml/min. (hazard ratio (HR) 15.41, 95% CI 3.55~16.69). Furthermore, cystatin C >1.35 mg/dl was an 
independent risk factor of mortality after PTA. (HR 4.13, 95% CI 1.02-16.69 )
conclusions: Cystatin C is a good surrogate marker for prediction of CIN or mortality in patients with PAD undergoing PTA.
Hazard ratio of mortality in PAD patients who underwent peripheral transluminal angioplasty
Variables HR 95% CI p value
Diabetes Mellitus 0.64 0.16 - 2.57 0.64
Hypertension 0.58 0.10 - 3.34 0.75
Age>75 2.66 0.67 - 10.60 0.19
Baseline eGFR < 60ml/min 1.73 1.74 0.34 - 8.86 0.63
Cystatine C > 1.35 mg/L 4.13 1.02 - 16.69 0.04
